Розсіяний склероз: патогенез і лікування

І.А. Завалишин, А.В. Переседова, НДІ неврології РАМН, Москва (директор– професор З. А. Сусліна)

Література

2. Розсіяний склероз. Вибрані питання теорії і практики. Під ред. І.А. Завалішина, В.І. Головкіна. – М.: ТОВ «Ельф ІПР», 2000. – 640 с.

3. Євтушенко С.К., Дерев’янко І.М. Магнітно-резонансна томографія в діагностиці розсіяного склерозу / / Журнал неврології і психіатрії ім. С.С. Корсакова. – 2001. – Т.101, № 4. – С.61-64.

4. Ciess R., Maurer M., Linker R. et al. A null mutation in the CNTF gene is associated with early onset of multiple sclerosis / / Arch. Neurol. – 2002. – Vol. 59. – P. 407-409.

5. Comi G., Filippi M., Barkhof F. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study / / Lancet. – 2001. – Vol. 357. – P. 1576-1582.

6. European Study Group on Interferon beta-lb in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon ?-lb in treatment of secondary progressive multiple sclerosis / / Lancet. – 1998. – Vol. 352. – P. 1491-1497.

7. Fazekas F., Strasser-Fuchs S., Kollegger H. et al. Apolipoprotein Ee4 is associated with rapid progression of multiple sclerosis / / Neurology. – 2001. – Vol. 57. – P. 853-857.

8. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis / / Neurology. – 2002. – Vol. 58. – P. 169-178.

9. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives [Invited review] / / Brain – 1997. – Vol. 120. – P. 865-916.

10. Jacobs LD, Beck RW, Simon JH et al., CHAMPS Study Group. Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis / / N. Engl. J. Med. – 2000. – Vol. 343. – P. 898-904.

11. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-la for disease progression in exacerbating-remitting multiple sclerosis / / Ann. Neurol. – 1996. – Vol. 39. – P.285-294.

12. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial / / Neurology. – 1995. – Vol. 45. – P. 1268-1276.

13. Johnson KP, Calabresi PA Interferon-?-lb: prophylactic therapy in multiple sclerosis / / Handbook of multiple sclerosis. Ed. SDCook. 3nd ed. – Marcel Dekker Inc. – 2001. – P. 503-518.

загрузка...

14. Kornek В., Storch M., Bauer J. et al. Distribution of calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis / / Brain. – 2001. – Vol. 124. – P. 1114-1124.

15. LoPachin R., Lehning E. Mechanisms of calcium entry during axon injury and degeneration / / Toxicol. Appl. Pharmacol. – 1997. – Vol. 143. – P. 233-244.

16. Lucchinetti C., Brueck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis / / Brain Pathol. – 1996. – Vol. 6. – P.259-274.

17. Neumann H., Cavalie A., Jenne D., Wekerle H. Induction of MHC class I genes in neurons / / Science. – 1995. – Vol. 269. – P. 549-552.

18. Panitch H. Prophylactic therapy – glatiramer acetate (Copaxone) / /Handbook of multiple sclerosis. Ed. SDCook. 3nd ed. – Marcel Dekker Inc. – 2001. – P. 541-560.

19. Patten SB What is the best approach to treating interferon-induced depression in people with multiple sclerosis? / / J. Neurosc. – 2001. – Vol. 26. – P. 66.

20. Patten SB, Fridhandler S., Beck CA, Luanne MM Depressive symptoms in a treated multiple sclerosis cohort / / Multiple Sclerosis. – 2003. -Vol. 9. – P. 616-620.

21. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon ?-1a in relapsing-remitting multiple sclerosis / / Lancet. – 1998. – Vol. 352. – P. 1498-1504.

22. Rieckmann P., Maurer M. Anti-inflammatory strategies to prevent axonal injury in multiple sclerosis / / Curr. Opin. Neurol. – 2002. – Vol. 15. – P. 361-370.

23. Smith KJ, Hall SM Factors directly affecting impulse transmission in inflammatory demyelinating disease: recent advances in our understanding / / Curr. Opin. Neurol. – 2001. – Vol. 14. – P. 289-298.

24. SPECTRIMS Study Group. Randomized controlled trial of interferon-?-1a in secondary progressive MS. Clinical results / / Neurology. – 2001. – Vol. 56. – P. 1496-1504.

25. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentral, randomized double bind, placebo-controlled trial / / Neurology. – 1993. – Vol. 43. – P. 655-661.

26. Trapp BD, Ransohoff RM, Fisher E., Rudick RA Neurodegeneration in multiple sclerosis: relationship to neurological disability / / Neurosc. – 1999. – Vol. 5. – P. 48-57.

27. Waxman SG Loss and restoration of impulse conduction in disorders of myelin / / Handbook of multiple sclerosis. Ed. SDCook. 3nd ed. – Marcel Dekker Inc. – 2001. – P. 257-288.

28. Waxman SG Transcriptional channelopathies: an emerging class of disorders / / Neurosci. – 2001. -Vol. 2. – P. 652-659.

Tags: , ,